NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Recurrent Mantle Cell Lymphoma

Interventions: Drug: temsirolimus

First Posted Date: 2003-01-27

Last Posted Date: 2014-04-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00033267

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Procedure: Conventional Surgery
Drug: Imatinib Mesylate

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT00028002

Locations: 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Phase 2

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT00002589

Locations: 🇺🇸
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States

Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Primary Peritoneal Cavity Cancer
Stage III Ovarian Epithelial Cancer
Recurrent Ovarian Epithelial Cancer
Fallopian Tube Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: thalidomide
Drug: tamoxifen citrate
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 139

Registration Number: NCT00041080

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Phase 2

Completed

Conditions: Uterine Carcinosarcoma
Recurrent Uterine Corpus Sarcoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Thalidomide

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00025506

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer
Thromboembolism

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020189

Locations: 🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
de Novo Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: decitabine
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00049582

Locations: 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada

Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020111

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States

and more 49 locations